August 11, 2021Open Access

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Key Points

Key points are not available for this paper at this time.

Abstract

CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Raphael J. Landovitz

Deborah Donnell

Meredith E. Clement

Journals

Civil War Book Review

New England Journal of Medicine

Actions

Institutions

Johns Hopkins University

National Institutes of Health

Cornell University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider